Humacyte enters $60M at-the-market equity offering with TD Cowen

Humacyte, Inc.

Up to $60M in common stock may be sold from time to time through TD Securities (USA) LLC as agent.
TD Cowen will receive a commission of up to 3.0% of gross proceeds.
Net proceeds to fund commercialization of Symvess in vascular trauma, pipeline, and working capital.
Company is not obligated to sell any shares; ATM allows sales at prevailing market prices.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Humacyte, Inc. entered into Sales Agreement with TD Securities (USA) LLC valued at aggregate offering price of up to $60,000,000 (effective 2025-12-16).

Action: entry
Agreement: atm program
Counterparty: TD Securities (USA) LLC
Value: aggregate offering price of up to $60,000,000
Effective: 2025-12-16

Exact text from the filing

On December 16, 2025, Humacyte, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with TD Securities (USA) LLC, as agent (“TD Cowen”), under which the Company may offer and sell its common stock, par value $0.0001 per share, from time to time having an aggregate offering price of up to $60 ,000,000 (the “Shares”) during the term of the Agreement through TD Cowen, acting as agent.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-121674

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.